A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01009463
First received: November 5, 2009
Last updated: July 10, 2014
Last verified: August 2013
  Purpose

The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)


Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: FF/GW642444 Inhalation Powder
Drug: GW642444 Inhalation Powder
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: HZC102871: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean [ Time Frame: From the start of the double blinded study medication until Visit 11 (Week 52)/Early Withdrawal ] [ Designated as safety issue: No ]
    The annual rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations during the treatment (trt) period (per participant [par.] per year) was assessed. An exacerbation of COPD, is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptoms (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. The COPD exacerbation was categorized as mild, moderate and severe by the investigator. Mild: worsening symptoms of COPD that were self-managed by the par. without the use of oral corticosteroids or antibiotics; Moderate: worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics; Severe: worsening symptoms of COPD that required treatment with in-patient hospitalization.


Secondary Outcome Measures:
  • Time to First Occurrence of Moderate or Severe COPD Exacerbation [ Time Frame: From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal ] [ Designated as safety issue: No ]
    Time to first occurrence analyzed by using a Cox proportional hazards model with covariates of treatment, smoking status at screening (stratum), baseline disease severity (pre-dose Day 1 % predicted FEV1) and centre grouping. An exacerbation of COPD is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptoms (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. A moderate exacerbation is defined as worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics. A severe exacerbation is defined as worsening symptoms of COPD that required treatment with in-patient hospitalization. The number of participants with a moderate or severe COPD exacerbation while on treatment are presented.

  • Annual Rate of Exacerbations Requiring Systemic/Oral Corticosteroids Expressed as Least Square Mean [ Time Frame: From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal ] [ Designated as safety issue: No ]
    The annual rate of COPD exacerbations during the treatment period (per participant per year) that required systemic/oral corticosteroids was assessed. An exacerbation of COPD is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptom (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. The COPD exacerbation was categorized as mild, moderate, and severe by the investigator. Mild: worsening symptoms of COPD that were self-managed by the participant. Mild exacerbations were not associated with the use of oral corticosteroids or antibiotics. Moderate: worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics. Severe: worsening symptoms of COPD that required treatment with in-patient hospitalization.

  • Change From Baseline in Trough FEV1 at Week 52 (Visit 11) [ Time Frame: Baseline to Visit 11 (Week 52)/Early Withdrawal ] [ Designated as safety issue: No ]
    Pulmonary function was measured by forced expiratory volume in one second (FEV1). Trough FEV1 was defined as the 24-hour post-dose FEV1 assessment, which was obtained at each visit. Analysis performed using a repeated measures model with covariates of treatment, smoking status at Screening (stratum), baseline (pre-dose Day 1), centre grouping, Week, Week by Baseline, and Week by treatment interactions.


Enrollment: 1626
Study Start Date: September 2009
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FF/GW642444 Inhalation Powder 100/25 mcg QD
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
Drug: FF/GW642444 Inhalation Powder
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
Experimental: FF/GW642444 Inhalation Powder 200/25 mcg QD
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
Drug: FF/GW642444 Inhalation Powder
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
Experimental: FF/GW642444 Inhalation Powder 50mcg/25mcg QD
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
Drug: FF/GW642444 Inhalation Powder
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
Experimental: GW642444 25mcg QD
Long Acting Beta Agonist(LABA)
Drug: GW642444 Inhalation Powder
Long Acting Beta Agonist(LABA) Inhalation Powder via DPI

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type of subject: outpatient
  • Informed consent: Subjects must give their signed and dated written informed consent to participate.
  • Gender: Male or female subjects A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g., age appropriate, history of vasomotor symptoms. However in questionable cases, a blood sample with FSH > 40MIU/ml and estradiol <40pg/ml (<140 pmol/L) is confirmatory. OR

Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e., in accordance with the approved product label and the instructions of the physician for the duration of the study - screening to follow-up contact):

  • Complete abstinence from intercourse from screening until the Follow-Up Phone Contact; or
  • Male partner is sterile (vasectomy with documentation of azoospermia) prior to female subject entry into the study, and this male partner is the sole partner for that subject; or
  • Implants of levonorgestral inserted for at least 1 month prior to the study medication administration but not beyond the third successive year following insertion; or
  • Injectable progestogen administered for at least 1 month prior to study medication administration and administered until the Follow-Up Phone Contact; or
  • Oral contraceptive (combined or progestogen only) administered for at least one monthly cycle prior to study medication administration; or
  • Double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent (foam/gel/film/cream/suppository); or
  • An intrauterine device (IUD), inserted by a qualified physician, with published data showing that the highest expected failure rate is less than 1% per year; or
  • Estrogenic vaginal ring; or
  • Percutaneous contraceptive patches

    • Age: ≥40 years of age at Screening (Visit 1)
    • COPD diagnosis: Subjects with a clinical history of COPD in accordance with the following definition by the American Thoracic Society/European Respiratory Society [Celli, 2004]: COPD is a preventable and treatable disease characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences.
    • Tobacco use: Subjects with a current or prior history of ≥10 pack-years of cigarette smoking at Screening (Visit 1). Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or cigar use cannot be used to calculate pack-year history. Number of pack years = (number of cigarettes per day/20) x number of years smoked
    • Severity of Disease:
  • Subject with a measured post-albuterol/salbutamol FEV1/FVC ratio of ≤0.70 at Screening (Visit 1)
  • Subjects with a measured post-albuterol/salbutamol FEV1 <70% of predicted normal values calculated (via centralized vendor equipment) using NHANES III reference equations [Hankinson, 1999] at Screening (Visit 1). Post-bronchodilator spirometry will be performed approximately 10-15 minutes after the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via an MDI with a valved-holding chamber. The study provided central spirometry equipment will calculate the FEV1/FVC ratio and FEV1 percent predicted values.

    • History of Exacerbations: A documented history (e.g., medical record verification) of at least one COPD exacerbation in the 12 months prior to Visit 1 that required either oral corticosteroids, antibiotics and/or hospitalization. Prior use of antibiotics alone does not qualify as an exacerbation history unless the use was associated with treatment of worsening symptoms of COPD, such as increased dyspnea, sputum volume, or sputum purulence (color). Subject verbal reports are not acceptable.

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

  • Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD)
  • α1-antitrypsin deficiency: Subjects with α1-antitrypsin deficiency as the underlying cause of COPD
  • Other respiratory disorders: Subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
  • Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1)
  • Chest X-ray (or CT scan): Subjects with a chest X-ray (or CT scan) that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD. A chest X-ray must be taken at Screening (Visit 1) if a chest X-ray or CT scan is not available within 6 months prior to Visit 1. For sites in Germany, if a chest X-ray (or CT scan) is not available in the 6 months preceding Screening (Visit 1), the subject will not be eligible for the study.
  • Risk Factors for Pneumonia: immune suppression (HIV, Lupus, etc) or other risk for pneumonia (e.g. neurological disorders affecting control of the upper airway, such as Parkinson's, Myasthenia Gravis, etc).
  • A moderate and severe COPD exacerbation that has not resolved at least 14 days prior to Visit 1 and at least 30 days following the last dose of oral corticosteroids (if applicable).
  • Pneumonia and/or moderate and severe COPD exacerbation at Visit 1 Note: Subjects who experience a pneumonia and/or exacerbation at Screening (Visit 1) must be not continue in the study, but may be re-screened at a later time provided the pneumonia and/or COPD exacerbation has resolved prior to the re-screening visit. At the Re-screening Visit, the chest x-ray should confirm resolution of pneumonia. The Re-screening Visit must be conducted at least ≥ 14 days following the resolution date of the exacerbation and/or pneumonia and at least 30 days following the last dose of oral corticosteroids (if applicable).
  • Other diseases/abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular (i.e., pacemaker), neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  • Peptic Ulcer disease: Subjects with clinically significant peptic ulcer disease that is uncontrolled.
  • Hypertension: Subjects with clinically significant hypertension that is uncontrolled.
  • Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded if the subject has been considered cured within 5 years since diagnosis.
  • Drug/food allergy: Subjects with a history of hypersensitivity to any of the study medications (e.g., beta-agonists, corticosteroid) or components of the inhalation powder (e.g., lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates the subject's participation will also be excluded.
  • Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years
  • Medication prior to spirometry: Subjects who are medically unable to withhold their albuterol/salbutamol and/or their ipratropium for the 4-hour period required prior to spirometry testing at each study visit.
  • Additional medication: Unable to stop using certain medications such as bronchodilators and corticosteroids for the protocol-specified times prior to Visit 1 (the Investigator will discuss the specific medications)
  • Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen prn use (i.e., ≤12 hours per day) is not exclusionary.
  • Sleep apnea: Subjects with clinically significant sleep apnea who require use of continuous positive airway pressure (CPAP) device or non-invasive positive pressure ventilation (NIPPV) device.
  • Pulmonary rehabilitation: Subjects who have participated in the acute phase of a Pulmonary Rehabilitation Program within 4 weeks prior to Screening (Visit 1) or who will enter the acute phase of a Pulmonary Rehabilitation Program during the study. Subjects who are in the maintenance phase of a Pulmonary Rehabilitation Program are not excluded.
  • Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.
  • Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study.
  • Prior use of study medication/other investigational drugs: Subjects who have previously been randomized to treatment with GW642444 Inhalation Powder in the B2C111045 study, randomized to treatment in the HZC111348 study or have participated in the HZC112207, HZC102871, HZC102970, or HZC110946 studies. Subjects who have received an investigational drug within 30 days of entry into this study (Screening), or within 5 drug half-lives of the investigational drug, whichever is longer.
  • Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01009463

  Hide Study Locations
Locations
United States, Alabama
GSK Investigational Site
Birmingham, Alabama, United States, 35294
GSK Investigational Site
Birmingham, Alabama, United States, 35235
GSK Investigational Site
Jasper, Alabama, United States, 35501
United States, Arizona
GSK Investigational Site
Peoria, Arizona, United States, 85381
GSK Investigational Site
Phoenix, Arizona, United States, 85012
GSK Investigational Site
Phoenix, Arizona, United States, 85050
GSK Investigational Site
Scottsdale, Arizona, United States, 85258
United States, California
GSK Investigational Site
Chula Vista, California, United States, 91911
GSK Investigational Site
Lincoln, California, United States, 95648
GSK Investigational Site
Long Beach, California, United States, 90822
GSK Investigational Site
Los Angeles, California, United States, 90048
GSK Investigational Site
Mission Viejo, California, United States, 92691
GSK Investigational Site
Palo Alto, California, United States, 94304
GSK Investigational Site
Poway, California, United States, 92064
GSK Investigational Site
Rancho Mirage, California, United States, 92270
GSK Investigational Site
Riverside, California, United States, 92506
GSK Investigational Site
Rolling Hills Estates, California, United States, 90274
GSK Investigational Site
Santa Monica, California, United States, 90404
GSK Investigational Site
Sepulveda, California, United States, 91343
GSK Investigational Site
Torrance, California, United States, 90503
United States, Connecticut
GSK Investigational Site
Stamford, Connecticut, United States, 06902
United States, Florida
GSK Investigational Site
Bay Pines, Florida, United States, 33744
GSK Investigational Site
Clearwater, Florida, United States, 33756
GSK Investigational Site
Clearwater, Florida, United States, 33755
GSK Investigational Site
Fort Myers, Florida, United States, 33916
GSK Investigational Site
Gainesville, Florida, United States, 32608
GSK Investigational Site
Miami, Florida, United States, 33136
GSK Investigational Site
Orlando, Florida, United States, 32822
GSK Investigational Site
Ormond Beach, Florida, United States, 32174
GSK Investigational Site
Tamarac, Florida, United States, 33321
GSK Investigational Site
Winter Park, Florida, United States, 32792
United States, Georgia
GSK Investigational Site
Austell, Georgia, United States, 30106
GSK Investigational Site
Decatur, Georgia, United States
GSK Investigational Site
Lawrenceville, Georgia, United States, 30046
United States, Illinois
GSK Investigational Site
Belleville, Illinois, United States, 62220
GSK Investigational Site
River Forest, Illinois, United States, 60305
United States, Indiana
GSK Investigational Site
Avon, Indiana, United States, 46123
GSK Investigational Site
Lafayette, Indiana, United States, 47904
GSK Investigational Site
Muncie, Indiana, United States, 47304-5547
GSK Investigational Site
Newburgh, Indiana, United States, 47630
United States, Iowa
GSK Investigational Site
Iowa City, Iowa, United States, 52242
United States, Kansas
GSK Investigational Site
Lenexa, Kansas, United States, 66215
GSK Investigational Site
Wichita, Kansas, United States, 67205
United States, Kentucky
GSK Investigational Site
Munfordville, Kentucky, United States, 42765
GSK Investigational Site
Owensboro, Kentucky, United States, 42301
United States, Louisiana
GSK Investigational Site
New Orleans, Louisiana, United States, 70115
GSK Investigational Site
Sunset, Louisiana, United States, 70584
United States, Maryland
GSK Investigational Site
Columbia, Maryland, United States, 21044
United States, Michigan
GSK Investigational Site
Southfield, Michigan, United States, 48034
GSK Investigational Site
St. Joseph, Michigan, United States, 49085
United States, Minnesota
GSK Investigational Site
Minneapolis, Minnesota, United States, 55407
GSK Investigational Site
Minneapolis, Minnesota, United States, 55402
GSK Investigational Site
Plymouth, Minnesota, United States, 55441
United States, Missouri
GSK Investigational Site
St. Charles, Missouri, United States, 63301
United States, Montana
GSK Investigational Site
Billings, Montana, United States, 59102
United States, New Hampshire
GSK Investigational Site
Lebanon, New Hampshire, United States, 03756
United States, New Jersey
GSK Investigational Site
Ocean, New Jersey, United States, 7712
United States, New York
GSK Investigational Site
New York, New York, United States, 10004
GSK Investigational Site
New York, New York, United States, 10029
United States, North Carolina
GSK Investigational Site
Elizabeth City, North Carolina, United States, 27909
GSK Investigational Site
Salisbury, North Carolina, United States, 28144
United States, Ohio
GSK Investigational Site
Dayton, Ohio, United States, 45406
United States, Oklahoma
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73103
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73120
GSK Investigational Site
Tulsa, Oklahoma, United States, 74136-8303
United States, Oregon
GSK Investigational Site
Medford, Oregon, United States, 97504
United States, Pennsylvania
GSK Investigational Site
Sellersville, Pennsylvania, United States, 18960
United States, Rhode Island
GSK Investigational Site
Johnston, Rhode Island, United States, 02919
United States, South Carolina
GSK Investigational Site
Anderson, South Carolina, United States, 29621
GSK Investigational Site
Charleston, South Carolina, United States, 29406-7108
GSK Investigational Site
Chester, South Carolina, United States, 29706
GSK Investigational Site
Gaffney, South Carolina, United States, 29340
GSK Investigational Site
Greenwood, South Carolina, United States, 29646
GSK Investigational Site
Greer, South Carolina, United States, 29651
GSK Investigational Site
Seneca, South Carolina, United States, 29678
United States, Tennessee
GSK Investigational Site
Chattanooga, Tennessee, United States, 37421
GSK Investigational Site
New Tazewell, Tennessee, United States, 37824-1409
United States, Texas
GSK Investigational Site
Austin, Texas, United States, 78705
GSK Investigational Site
Boerne, Texas, United States, 78006
GSK Investigational Site
Forth Worth, Texas, United States, 76109
GSK Investigational Site
Kingwood, Texas, United States, 77339
GSK Investigational Site
Lake Jackson, Texas, United States, 77566
GSK Investigational Site
San Antonio, Texas, United States, 78229
GSK Investigational Site
Temple, Texas, United States, 76508
United States, Vermont
GSK Investigational Site
South Burlington, Vermont, United States, 05403
United States, Virginia
GSK Investigational Site
Abingdon, Virginia, United States, 24210
GSK Investigational Site
Charlottesville, Virginia, United States, 22911
GSK Investigational Site
Fredericksburg, Virginia, United States, 22401
GSK Investigational Site
Richmond, Virginia, United States, 23225
GSK Investigational Site
Virgina Beach, Virginia, United States, 23455
United States, Washington
GSK Investigational Site
Lakewood, Washington, United States, 98499
GSK Investigational Site
Spokane, Washington, United States, 99204
GSK Investigational Site
Tacoma, Washington, United States, 98405
GSK Investigational Site
Wenatchee, Washington, United States, 98801
Argentina
GSK Investigational Site
Cipolletti, Río Negro, Argentina, R8324EMB
GSK Investigational Site
Buenos Aires, Argentina, C1425BEN
GSK Investigational Site
Buenos Aires, Argentina, C1424BSF
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, C1426ABP
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, C1428DDE
GSK Investigational Site
Mendoza, Argentina, M5500CCG
Australia, Australian Capital Territory
GSK Investigational Site
Garran, Australian Capital Territory, Australia, 2606
Australia, Queensland
GSK Investigational Site
Cairns, Queensland, Australia, 4870
GSK Investigational Site
Kippa Ring, Queensland, Australia, 4021
Australia, South Australia
GSK Investigational Site
Daw Park, South Australia, Australia, 5041
Australia, Victoria
GSK Investigational Site
Frankston, Victoria, Australia, 3199
GSK Investigational Site
Geelong, Victoria, Australia, 3220
GSK Investigational Site
Heidelberg, Victoria, Australia, 3084
Australia, Western Australia
GSK Investigational Site
Nedlands, Western Australia, Australia, 6009
Canada, British Columbia
GSK Investigational Site
Vancouver, British Columbia, Canada, V5Z 4E1
Canada, Newfoundland and Labrador
GSK Investigational Site
St. John's, Newfoundland and Labrador, Canada, A1E 2E2
Canada, Ontario
GSK Investigational Site
Burlington, Ontario, Canada, L7N 3V2
GSK Investigational Site
Corunna, Ontario, Canada, N0N 1G0
GSK Investigational Site
Sudbury, Ontario, Canada, P3E 1H5
GSK Investigational Site
Toronto, Ontario, Canada, M3H 5S4
GSK Investigational Site
Toronto, Ontario, Canada, M4P 1P2
GSK Investigational Site
Toronto, Ontario, Canada, M9W 4L6
Canada, Quebec
GSK Investigational Site
Montreal, Quebec, Canada, H2R 1V6
Canada
GSK Investigational Site
Quebec, Canada, G1V 4G5
Chile
GSK Investigational Site
Temuco, Región De La Araucania, Chile, 4800798
GSK Investigational Site
Valparaiso, Valparaíso, Chile, 2341131
GSK Investigational Site
Santiago, Chile, 8380453
Estonia
GSK Investigational Site
Rakvere, Estonia, 44316
GSK Investigational Site
Tallinn, Estonia, 10611
GSK Investigational Site
Tallinn, Estonia, 10117
GSK Investigational Site
Tartu, Estonia, 51014
Germany
GSK Investigational Site
Geesthacht, Schleswig-Holstein, Germany, 21502
GSK Investigational Site
Berlin, Germany, 10367
GSK Investigational Site
Berlin, Germany, 10717
GSK Investigational Site
Berlin, Germany, 12203
Italy
GSK Investigational Site
Eboli (SA), Campania, Italy, 84025
GSK Investigational Site
Telese Terme (BN), Campania, Italy, 82037
GSK Investigational Site
Ferrara, Emilia-Romagna, Italy, 44100
GSK Investigational Site
Roma, Lazio, Italy, 00163
GSK Investigational Site
Roma, Lazio, Italy, 00135
GSK Investigational Site
Genova, Liguria, Italy, 16132
GSK Investigational Site
Milano, Lombardia, Italy, 20142
GSK Investigational Site
Tradate (VA), Lombardia, Italy, 21049
GSK Investigational Site
Torrette (AN), Marche, Italy, 60126
GSK Investigational Site
Cassano Murge (BA), Puglia, Italy, 70020
Mexico
GSK Investigational Site
Tijuana, Baja California Norte, Mexico, 22320
GSK Investigational Site
Guadalajara, Jalisco, Mexico, 44100
GSK Investigational Site
Zapopan, Jalisco, Mexico, 45040
GSK Investigational Site
Monterrey, Nuevo León, Mexico, 64060
Netherlands
GSK Investigational Site
Bunnik, Netherlands, 3981 LB
GSK Investigational Site
Enschede, Netherlands, 7513 ER
GSK Investigational Site
Etten-leur, Netherlands, 4872 LA
GSK Investigational Site
Harderwijk, Netherlands, 3844 DG
GSK Investigational Site
Heerlen, Netherlands, 6419 PC
GSK Investigational Site
Helmond, Netherlands, 5707 HA
GSK Investigational Site
Nijverdal, Netherlands, 7442 LS
GSK Investigational Site
Rotterdam, Netherlands, 3078 HT
GSK Investigational Site
Sneek, Netherlands, 8601 ZK
GSK Investigational Site
Spijkenisse, Netherlands, 3207 NB
GSK Investigational Site
Veldhoven, Netherlands, 5504 DB
GSK Investigational Site
Voerendaal, Netherlands, 6367 ED
Peru
GSK Investigational Site
Jesus Maria, Lima, Peru, Lima 11
GSK Investigational Site
San Martin de Porres, Lima, Peru, Lima 31
GSK Investigational Site
Lima, Peru, Lima 41
GSK Investigational Site
Lima, Peru, Lima 27
Philippines
GSK Investigational Site
Dagupan City, Philippines, 2400
GSK Investigational Site
Quezon City, Philippines, 1100
GSK Investigational Site
Quezon City, Philippines, 1109
GSK Investigational Site
Quezon City, Philippines, 1101
South Africa
GSK Investigational Site
Cape Town, Gauteng, South Africa, 7505
GSK Investigational Site
Mueckelneck, Gauteng, South Africa, 0001
GSK Investigational Site
Boksburg North, South Africa, 1459
GSK Investigational Site
Cape Town, South Africa, 8001
GSK Investigational Site
Durban, South Africa, 4001
GSK Investigational Site
Durban, South Africa, 4091
GSK Investigational Site
Groenkloof, South Africa, 0181
GSK Investigational Site
Lynnwood Manor, South Africa, 0081
GSK Investigational Site
Lyttleton, South Africa, 0140
GSK Investigational Site
Paarl, South Africa, 7646
GSK Investigational Site
Panorama, South Africa, 7500
GSK Investigational Site
Reiger Park, South Africa, 1459
GSK Investigational Site
Somerset West, South Africa, 7130
GSK Investigational Site
Witbank, South Africa, 1034
Sweden
GSK Investigational Site
Göteborg, Sweden, SE-412 63
GSK Investigational Site
Göteborg, Sweden, SE-413 45
GSK Investigational Site
Höllviken, Sweden, SE-236 51
GSK Investigational Site
KIL, Sweden, SE-665 30
GSK Investigational Site
Örebro, Sweden, SE-703 62
United Kingdom
GSK Investigational Site
Doncaster, United Kingdom, DN9 2HY
GSK Investigational Site
Liverpool, United Kingdom, L9 7AL
GSK Investigational Site
London, United Kingdom, SW17 0RE
GSK Investigational Site
London, United Kingdom, NW3 2PF
GSK Investigational Site
London, United Kingdom, E7 8QP
GSK Investigational Site
Newcastle upon Tyne, United Kingdom, NE7 7DN
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided by GlaxoSmithKline

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01009463     History of Changes
Other Study ID Numbers: 102871
Study First Received: November 5, 2009
Results First Received: May 30, 2013
Last Updated: July 10, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
COPD
Safety
FEV1
Efficacy

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Chronic Disease
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes
Fluticasone
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents

ClinicalTrials.gov processed this record on September 18, 2014